Zambon Innovation

 

A tradition of innovation

Since it was established in 1906, Zambon has been recognised for its long tradition of Research and Development which led to the discovery - and subsequent commercialization - of notable molecules such as N-acetylcysteine, fosfomycin trometamol and ibuprofen arginine, which over time achieved international recognition and are now widely used treatments for prevalent respiratory disorders, non-complicated urinary infections and pain.

"Offering products, services and solutions that help people to breathe well and live better" has been the new mission of Zambon since 2007, which saw a marked expansion of its horizons in Research and Development, comprehensively transforming the model through which the company innovates its products.

Thanks to this new mission, which sees the patient and quality of life as the central focus of the company, today Zambon is dedicated not only to developing new chemical entities but to improving existing ones with the aim of offering patients more effective therapeutic solutions, with improved tolerability, that are capable of improving their standard of living, particularly for those affected by chronic disorders.
Zambon innovation therefore focuses on both new and existing products, with a view to continuously improving their performance in order to satisfy a therapeutic demand that is increasingly focused not only on treating the symptoms, but on guaranteeing patients high standards of the quality of life when diagnosed with prevalent chronic illnesses.

The research model has been consistently redefined according to the logic of "Open Innovation", pairing internal research with the exploration of international scenarios through the development of a dynamic and close-knit network of relations with universities, research centres, technology transfers, start-ups and biotech companies, which today represent a broad source of discovery with great innovative potential.

Today the Innovation & Medical Sciences division is run based on a flexible and integrated model which, as well as internationalising opportunities, operates through co-development agreements and partnerships, focusing particularly on development projects having completed the pre-clinical phase and on projects joined at the end of phase II.